Immunohistochemical Study on the Expression of c-erbB-2 Oncoprotein in Gastric Cancer

胃癌c-erbB-2致癌蛋白表現的免疫組織化學研究

10.6440/TZUCMJ.199509.0159

李威傑(Wei-Jen Lee)；洪瑞隆(Ruey-Long Hong)；孫家棟(Chia-Tung Shun)；陳炯年(Chiung-Nien Chen)；陳楷模(Kai-Mo Chen)

胃癌 ； c-erbB-2致蛋白 ； 免疫組織化學法 ； Gastric cancer ； c-erbB-2 oncoprotein ； immunohistochemistry

慈濟醫學雜誌

7卷3期（1995 / 09 / 01）

159 - 165

英文

Expression of the c-erbB-2 oncogene protein was investigated by immunohistochemistry in 149 cases of primary gastric cancer. Positive staining, regarded as on indication of gene amplification, was evident in 38(25.5%) of the tumors. Of various clinicopathological factors considered, a statistically significant difference in association with frequency of expression was noted only for the histological type(39.3% positive staining in intestinal type, 15.4% in diffuse type, P＜0.01), but not for age, sex, tumor site, gross type, size, depth of invasion, node metastases, and TNM stage. However, in seven of ten metastatic lymph nodes, the cancer cells stained positive for c-erbB-2, even when the primary tumor stained negative. This finding suggests that c-erbB-2 overexpression may be associated with the metastatic potential of gastric cancer. The 2-year survival rates of patients with positive and negative c-erbB-2 protein were 44% and 56%, respectively, which is without statistical difference. In subgroup analysis, erbB-2 expression was not associated with poorer prognosis in the intestinal type or the diffuse type gastric cancer. These findings indicate that, in the case of human gastric cancer, expression of c-erbB-2 protein is correlated with tumor histological type, and that the presence or absence of c-erbB-2 protein may serve as on indicator for potential of distant metastases.

Expression of the c-erbB-2 oncogene protein was investigated by immunohistochemistry in 149 cases of primary gastric cancer. Positive staining, regarded as on indication of gene amplification, was evident in 38(25.5%) of the tumors. Of various clinicopathological factors considered, a statistically significant difference in association with frequency of expression was noted only for the histological type(39.3% positive staining in intestinal type, 15.4% in diffuse type, P＜0.01), but not for age, sex, tumor site, gross type, size, depth of invasion, node metastases, and TNM stage. However, in seven of ten metastatic lymph nodes, the cancer cells stained positive for c-erbB-2, even when the primary tumor stained negative. This finding suggests that c-erbB-2 overexpression may be associated with the metastatic potential of gastric cancer. The 2-year survival rates of patients with positive and negative c-erbB-2 protein were 44% and 56%, respectively, which is without statistical difference. In subgroup analysis, erbB-2 expression was not associated with poorer prognosis in the intestinal type or the diffuse type gastric cancer. These findings indicate that, in the case of human gastric cancer, expression of c-erbB-2 protein is correlated with tumor histological type, and that the presence or absence of c-erbB-2 protein may serve as on indicator for potential of distant metastases.